ABBV

AbbVie Inc. ABBV logo

NYSE Healthcare

$254.58

+0.10 (+0.04%)

Updated: 7/17/2026, 8:55:00 PM

Open

$257.00

High

$260.73

Low

$253.56

Prev Close

$254.39

Volume

5.21M

Price History

Why Is ABBV — Flat Today?

+0.04%

AbbVie sees marginal gain, trails healthcare sector

AbbVie (ABBV) recorded a modest gain of 0.0393% today, closing at $254.58 on a volume of 5.21 million shares. This slight uptick occurred as the broader healthcare sector advanced by 0.40%, indicating ABBV underperformed its peers. The day's movement appears to be largely influenced by general market dynamics rather than specific company news.

Key Drivers

General Market Dynamics

AbbVie's stock experienced a minimal positive change, suggesting its movement was primarily influenced by broader market sentiment rather than specific company-related catalysts.

Generated by Highly Regarded's proprietary market analysis engine. Not financial advice.

Jul 17 — +0.0% AbbVie sees marginal gain, trails healthcare sector

Jul 16 ▲ +3.6% AbbVie Rises on Positive Autoimmune Market Outlook, Outperforms Sector

Jul 15 ▼ -0.2% AbbVie Dips Slightly Amid Lower Volume, Underperforms Sector

Jul 14 ▼ -1.3% AbbVie (ABBV) shows relative strength on a down day for the sector

Jul 13 — -0.0% AbbVie Slips Marginally, Underperforms Sector

Jul 10 ▼ -0.7% AbbVie posts modest decline, outperforms sector on light volume

Jul 9 ▼ -1.1% AbbVie (ABBV) Shares Decline, Outpacing Sector Downturn

Jul 8 ▼ -1.0% AbbVie (ABBV) Dips Slightly, Outperforming Broader Healthcare Sector

Jul 7 — -0.1% AbbVie Edges Down Slightly Amidst Strong Sector and Product News

Jul 6 ▼ -2.5% AbbVie shares decline, underperforming broader healthcare sector

Jul 3 — +0.0% ABBV Trading Halted as US Markets Observe Independence Day Holiday

Jul 2 ▲ +3.9% AbbVie Surges to New 52-Week High Amidst Pharma Sector Optimism

Jul 1 ▼ -0.2% AbbVie sees modest dip, outperforms sector's broader decline

Jun 30 ▼ -1.0% AbbVie Dips Modestly, Outperforming Sector Amid Valuation Scrutiny

Jun 29 ▲ +0.2% AbbVie posts modest gain, underperforming healthcare sector

Mar 31 ▲ +1.5% AbbVie (ABBV) Climbs on Analyst Support and Aesthetics Momentum

Mar 30 ▲ +1.8% AbbVie (ABBV) Rises Amidst Positive Dividend News and Sector Gains

Mar 27 ▼ -0.9% ABBV dips slightly amid sector weakness, remains attractive for dividends

Mar 26 ▲ +1.9% AbbVie (ABBV) Rises on Positive Catalysts, Pipeline Developments

Mar 25 ▲ +1.0% ABBV Rises Slightly Amidst Positive Sentiment and Sector Underperformance

Mar 24 ▲ +0.1% AbbVie (ABBV) Up Slightly Amidst Mixed Sentiment

Mar 23 ▼ -0.5% ABBV Declines Amidst Sector Weakness and Competitive Pressures

Mar 20 ▼ -0.6% ABBV Declines Amidst Sector Weakness and Competitive Pressure

Mar 19 ▼ -1.0% ABBV down 1.00% as competition heats up in immunology

Mar 18 ▼ -5.2% AbbVie (ABBV) Slides Amidst Healthcare Sector Weakness

Mar 17 ▼ -0.8% ABBV Declines Slightly Amid Sector Weakness

Mar 16 ▲ +0.7% AbbVie (ABBV) Up Slightly on Positive Obesity Drug Data

Mar 13 ▼ -2.5% AbbVie (ABBV) Drops Amidst Mixed Signals, Offsetting Positive News

Mar 12 ▼ -1.0% AbbVie (ABBV) dips slightly amid mixed signals, broader sector decline

Mar 11 ▲ +0.3% AbbVie (ABBV) modestly up on positive drug data

Highly Regarded Analysis

Updated Jul 17, 2026 • Refreshes daily

Rating

Highly Regarded

Risk

Medium

Target

$273.25

Type

Standard

Executive Summary

AbbVie Inc. is a research-based biopharmaceutical company in a pivotal transition period, moving beyond the Humira era. The company is reshaping its portfolio through next-generation immunology drugs like Skyrizi and Rinvoq, strategic acquisitions, and global market expansion. AbbVie reported strong first-quarter 2026 financial results with robust portfolio growth across immunology and neuroscience, leading to a raised full-year adjusted diluted EPS guidance for 2026.

Bull Case

The bull case for ABBV rests on the continued strong performance and growth of its next-generation immunology drugs, Skyrizi and Rinvoq, which have secured patent protection extending to 2037 for Rinvoq. Successful integration and accretive contributions from recent strategic acquisitions, such as Apogee Therapeutics and Cerevel, along with continued advancements in its diverse pipeline in neuroscience and oncology, are expected to offset the impact of the Humira patent cliff. Raised full-year guidance and positive analyst sentiment underpin the potential for sustained revenue and earnings growth.

Bear Case

The bear case involves a more significant and faster erosion of sales from Humira and other mature products than currently anticipated. Increased competitive pressures in the immunology market and potential setbacks or delays in pipeline trial results or new drug approvals could negatively impact future financial performance and earnings growth. Additionally, the company's high debt levels and potential challenges with liquidity could pose risks, especially if new acquisitions do not generate expected returns or if pricing pressures intensify.

Technical Outlook

The technical outlook for ABBV appears positive. The stock is in a rising trend channel in the medium term, indicating increasing optimism among investors. Technical indicators, including MACD and several moving averages, suggest a 'Strong Buy' or 'Buy' signal. There is no significant resistance in the price chart, suggesting potential for continued upward movement. The Relative Strength Index (RSI) is around 64-65, generally indicating a buy or neutral position.

Fundamental Health

AbbVie delivered robust first-quarter 2026 financial results with total net revenues of $15.002 billion, a 12.4% increase on a reported basis, and adjusted diluted EPS of $2.65. The company has raised its full-year 2026 adjusted diluted EPS guidance to $14.08 - $14.28. Key immunology drugs, Skyrizi and Rinvoq, are significant growth drivers, with Skyrizi global revenues increasing significantly. However, the company faces ongoing revenue decline from Humira due to biosimilar competition, and Imbruvica revenues also decreased in the first quarter of 2026. AbbVie has a high debt-to-equity ratio of -1102.7% and total liabilities of $143.08 billion compared to total assets of $136.46 billion, which indicates significant financial leverage. The trailing dividend yield is 2.65%.

Key Catalysts

Continued robust growth and market penetration of Skyrizi and Rinvoq.
Successful advancement and approval of key pipeline assets, particularly in neuroscience and oncology.
Effective integration and positive financial contributions from recent acquisitions, including Apogee Therapeutics, ImmunoGen, and Cerevel.
Strategic management of patent expirations and competitive landscape for existing blockbusters.
New drug approvals and label expansions across therapeutic areas.

Sources

tradingview.com syneticx.com abbvie.com alpha-sense.com investtech.com tipranks.com investing.com prnewswire.com public.com abbvie.com pharmaceutical-technology.com simplywall.st researchgate.net robinhood.com morningstar.com abbvie.com pharmavoice.com

This analysis was conducted by Highly Regarded's proprietary market analysis engine. It is not financial advice. Always do your own research and consult a financial advisor before making investment decisions.